On Demand

The IMPACT webinar series - guidance for Cardiovascular Physicians

Dr Sandy Gupta

Bernadette Downey

1. Dr Sandy Gupta and Bernadette Downey discuss the ‘deadly duo’ of smoking and cardiovascular disease and the health benefits of smoking cessation. They also highlight their experiences of the changing environment of smoking cessation services and re-enforce the need for a whole system approach across primary and secondary care.

On Demand

The IMPACT webinar series - guidance for General Practitioners and Nurses

Dr Stephen Gaduzo

Nurse Lisa Fendell

1. GP Stephen Gaduzo and Smoking Cessation Advisor Lisa Fendall discuss how smoking is a significant cause of long term diseases such as COPD, cardiovascular disease and diabetes and the substantial health benefits of quitting smoking for these patient groups.

On Demand

The IMPACT webinar series - guidance for Respiratory Physicians

Keir Lewis - Swansea University

1. Professor Keir Lewis discusses the burden of smoking and the impact that the subsequent chronic respiratory conditions in patients has on the NHS.

On Demand

XALKORI in ALK+ advanced NSCLC: Efficacy in a real world setting

Dr Shobhit Baijal

Dr Shobit Baijal explores the use of real world data to understand, in further detail, the use of Xalkori® in patients with ALK+ advanced NSCLC. He illustrates this by talking through a number of real world, retrospective, cohort study data that provides findings in support of sequential therapy with Xalkori®.

On Demand

Accurate and efficient detection of the ALK gene rearrangement in NSCLC

Professor John Gosney

After highlighting how lung cancer biopsy reports have changed dramatically within 10 years, Prof. John Gosney delves into our understanding behind the ALK gene and the gold-standard method to detect the ALK gene rearrangement.

On Demand

The use of XALKORI® within ROS1+ advanced NSCLC

Dr Rohit Lal

Dr Rohit Lal explains the use of Xalkori in ROS1+ advanced NSCLC through PROFILE 10011 study data before presenting real world data provided through a ROS1 clinical case study.

On Demand

Accurate and efficient detection of the ROS1 gene rearrangement in NSCLC

Professor John Gosney

After highlighting how lung cancer biopsy reports have changed dramatically within 10 years, Prof. John Gosney delves into our understanding behind the ROS1 gene and the gold-standard method to detect the ROS1 gene rearrangement.

On Demand

IBRANCE® (palbociclib) indication

Erling Thor Donnelly, PhD. Pfizer | Oncology Lead, Sweden & Nordics IBRANCE Collaboration Lead

Ibrance is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer:1

• In combination with an aromatase inhibitor;
• In combination with fulvestrant in women who have received prior endocrine therapy.

In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.

References
1. IBRANCE Summary of Product Characteristics

On Demand

IBRANCE® (palbociclib) mode of action

Pfizer

IBRANCE works synergistically with ET to prevent cell proliferation2,3
IBRANCE acts downstream from ER2,3. It inhibits CDK 4/6 and helps to control cancer cell proliferation by inducing G1 arrest and reducing cell cycle progression2,3
IBRANCE in combination with ET results in increased and sustained cell cycle arrest compared with ET alone2,3

References:
1. IBRANCE Summary of Product Characteristics
2. Rocca A, et al. Expert Opin Pharmacother. 2014;15(3):407-20
3. Cadoo KA, et al. Breast Cancer: Targets and Therapy. 2014;6:123-33

On Demand

IBRANCE® (palbociclib) dosing

Erling Thor Donnelly, PhD. Pfizer | Oncology Lead, Sweden & Nordics IBRANCE Collaboration Lead

FBCs are the only monitoring requirement with IBRANCE.1* Prior to initiating treatment with IBRANCE, patients should have their full blood count, liver function tests and urea and electrolytes testing, as well as testing as clinically required throughout treatment.1

It is recommended to monitor FBCs on Days 1 and 15 of the first cycle and on Day 1 of each cycle thereafter.1

For patients who experience a maximum of Grade 1 or 2 neutropenia in the first 6 cycles, FBCs for subsequent cycles should be monitored every 3 months, prior to the beginning of a cycle and as clinically indicated.

*Other tests as clinically required
1. IBRANCE Summary of Product Characteristics.